As artificial intelligence and advanced technologies transform the pharmaceutical industry, leaders face the challenge of harnessing innovation wit...
Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million o...
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA...
Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company specializing in the development of innovative dr...
Partnership pairs Applied StemCell's induced pluripotent stem cell technology with RoosterBio's engineered media, reagents, and scalable bioprocess syste...
Biocytogen and Whitehawk Therapeutics, Inc. announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytog...
Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfo...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of ...
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas Insilico Medicine ("Insilico" HKEX:3696), a ...
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slal...
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announce...
— NTB-928 is a bispecific T-cell engager engineered for selective killing of FOLR1-overexpressing tumor cells while sparing FOLR1-positive normal...
© 2026 Biopharma Boardroom. All Rights Reserved.
